In the SISPCT trial of 1,089 patients with severe sepsis or septic shock, high-dose intravenous sodium selenite did not lower 28-day mortality (28.3% against 25.5% on placebo).
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 3 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
In the SISPCT trial of 1,089 patients with severe sepsis or septic shock, high-dose intravenous sodium selenite did not lower 28-day mortality (28.3% against 25.5% on placebo). · pmid:27428731
An earlier trial of intravenous sodium selenite in 238 patients with sepsis found 39.7% mortality against 50.0% on placebo, a difference that was not significant in the intention-to-treat analysis. · pmid:17095947
In a phase I trial in 34 patients with therapy-resistant cancers, the maximum tolerated dose of intravenous sodium selenite was 10.2 mg/m2, with fatigue, nausea and cramps the commonest adverse events. · pmid:26102212
Proportion of the 3 claims about Sodium selenite standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
3 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Sodium selenite yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial. · pmid 27428731 · 2016
Observational evidence· resolved human data at the emerging tier: thin, or contested
Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. · pmid 17095947 · 2007
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study. · pmid 26102212 · 2015
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
3 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.